Prognostic Factors in the Recurrence of Stage I and II Squamous Cell Cancer of the Oral Cavity

Jones, Kathleen; Lodge-Rigal, R D; Reddick, Robert L.; Tudor, G; Shockley, W.

doi:10.1001/archotol.1992.01880050029006

Cited by 142 publications

(115 citation statements)

References 9 publications

Supporting

Mentioning

102

Contrasting

Unclassified

Order By: Relevance

“…In contrast to lip, tongue cancers tend to show aggressive biological and clinical behavior (Jones et al, 1992). Unfortunately, the increase in incidence has not been paralleled by the development of new therapeutic agents (Lasrado et al, 2014).…”

Section: Introductionmentioning

confidence: 99%

DOX-MTX-NPs Augment p53 mRNA Expression in OSCC Model in Rat: Effects of IV and Oral Routes

Abbasi¹,

Khiavi²,

Amir³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: Oral squamous cell carcinoma (OSCC) is the sixth most common malignancy worldwide. Cancer development and progression require inactivation of tumor suppressor genes and activation of proto-oncogenes. The well recognized mechanism of action demonstrated for chemotherapeutic agents is induction of apoptosis via reactivation of p53. In this context, we evaluate the efficacy of IV and oral routes of our novel PH and temperature sensitive doxorubicin-methotrexate-loaded nanoparticles (DOX-MTX NP) in affecting p53 profile in an OSCC rat model. Methods: In this study, 120 male rats were divided into 8 groups of 15 animals each. The new formulated DOX-MTX NP and free doxorubicin were IV and orally given to rats with 4-nitroquinoline-1-oxide induced OSCC. Results: Results showed that both DOX and DOX-MTX-NP caused significant increase in mRNA levels of P53 compared to the untreated group (p<0.000). With both DOX and DOX-MTX NP, the IV mode was more effective than the oral (gavage) route (p<0.000). Surprisingly, in oral mode, p53 mRNA was not affected in DOX treated groups (p>0.05), Nonetheless, both IV and oral administration of MTX-DOX NP showed superior activity (~3 fold) over free DOX in reactivation of p53 in OSCC (p<0.000). The effectiveness of oral route in group treated with nanodrug accounts for the enhanced bioavailability of nanoparticulated DOX-MTX compared to free DOX. Moreover, in treated groups, tumor stage was markedly related to the amount of p53 mRNA (p<0.05). Conclusion: Both oral and IV application of our novel nanodrug possesses superior activity over free DOX-in up-regulation of p53 in a OSCC model and this increase in p53 level associated with less aggressive tumors in our study. Although, impressive results obtained with IV form of nanodrug (-21 fold increase in p53 mRNA level) but both forms of nanodrug are effective in OSCC, with less toxicity normal cells.

show abstract

Section: Introductionmentioning

confidence: 99%

DOX-MTX-NPs Augment p53 mRNA Expression in OSCC Model in Rat: Effects of IV and Oral Routes

Abbasi¹,

Khiavi²,

Amir³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…recurrencia tumoral de alrededor 40%-50% en los pacientes con estadio avanzado, ocurriendo el 80% de estas recurrencias dentro de los 2 primeros años 4 .…”

unclassified

Manejo del cáncer de cabeza y cuello: ¿Radioterapia a quién, cuándo y por qué?

Vinés¹,

et al. 2017

Rev. Otorrinolaringol. Cir. Cabeza Cuello

View full text Add to dashboard Cite

show abstract

“…This tyrosine kinase receptor is connected to various downstream signaling targets involved in cellular proliferation, apoptosis, angiogenesis , invasion, and also metastasis. HER2 encoded by ERBB2 gene and is overexpressesd in over 80% of all HNSCC (Jones et al, 1992;Kim et al, 2001;Lippman and Hong, 2001;Kademani et al, 2005;Montoro et al, 2008;Sardari et al, 2012;Khademi et al, 2013). Combination chemotherapy and nanoparticle drug delivery put forwards significant promise in cancer treatment.…”

Section: New Formulated "Dox-mtx-loaded Nanoparticles" Downregulate Hmentioning

confidence: 99%

“…Oral squamous cells carcinomas (OSCCs) accounts for approximately 95% of all oral malignant neoplasms and for about 38% of all malignant head and neck tumors, especially the tongue and lip (Jones et al, 1992;Brandwein-Gensler et al, 2005;Bell et al, 2007). Unfortunately, the increase in incidence has not been paralleled by the development of new therapeutic agents and the 5-year survival rate remains at 50% over the past 30 years (Mesgari Abbasi et al, 2014c).…”

Section: Introductionmentioning

confidence: 99%

New formulated "DOX-MTX-loaded Nanoparticles" Down-regulate HER2 Gene Expression and Improve the Clinical Outcome in OSCCs Model in Rat: the Effect of IV and Oral Modalities

Abbasi

Amir²,

Hamishehkar³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: Oral squamous cell carcinoma (OSCC) remains as one of the most difficult malignancies to control because of its high propensity for local invasion and cervical lymph node dissemination. In this study, we evaluate the efficacy of our novel pH and temperature sensitive doxorubicin-methotrexate-loaded nanoparticles (DOX-MTX NP) in affecting HER2 expression profile in OSCC model in rat. Results: DOX-MTX-nanoparticle complexes caused significant decrease in mRNA level of HER2 compared to untreated cancers (p<0.05) and this finding was more pronounced with the IV mode (p<0.000). Surprisingly, HER2 mRNA was not affected in DOX treated as compared to the control group (p>0.05). On the other hand, in the DOX-MTX NP treated group, fewer tumors characterized with advanced stage and decreased HER2 paralleled improved clinical outcome (P<0.05). Moreover, the effectiveness of the oral route in the group treated with nanodrug accounted for the enhanced bioavailability of nanoparticulated DOX-MTX compared to free DOX. Furthermore, there was no significant difference in mRNA level of HER2 (p>0.05). Conclusions: Influence of HER2 gene expression is a new feature and mechanism of action observed only in dual action DOX-MTX-NPs treated groups. Down-regulation of HER2 mRNA as a promising marker and prognosticator of OSCC adds to the cytotoxic benefits of DOX in its new formulation. Both oral and IV application of this nanodrug could be used, with no preferences in term of their safety or toxicity. As HER2 is expressed abundantly by a wide spectrum of tumors, i DOX-MTX NPs may be useful for a wide-spectrum of lesions. However, molecular mechanisms underlying HER2 down regulation induced by DOX-MTX NPs remain to be addressed.

show abstract

Prognostic Factors in the Recurrence of Stage I and II Squamous Cell Cancer of the Oral Cavity

Cited by 142 publications

References 9 publications

DOX-MTX-NPs Augment p53 mRNA Expression in OSCC Model in Rat: Effects of IV and Oral Routes

DOX-MTX-NPs Augment p53 mRNA Expression in OSCC Model in Rat: Effects of IV and Oral Routes

Manejo del cáncer de cabeza y cuello: ¿Radioterapia a quién, cuándo y por qué?

New formulated "DOX-MTX-loaded Nanoparticles" Down-regulate HER2 Gene Expression and Improve the Clinical Outcome in OSCCs Model in Rat: the Effect of IV and Oral Modalities

Contact Info

Product

Resources

About